Phibro Animal Health (PAHC) just posted its Q3 2026 scorecard with revenue of US$383.5 million and basic EPS of US$0.59, while trailing 12 month revenue stands at US$1.5 billion and EPS at US$2.35, underpinned by trailing 12 month net income of US$95.2 million. The company has seen quarterly revenue move from US$309.3 million in Q2 2025 to US$383.5 million in Q3 2026, with basic EPS shifting from US$0.08 to US$0.59 over the same stretch. This release offers a check-in on how far margins have come and how durable that profitability looks.

See our full analysis for Phibro Animal Health.

With the headline numbers on the table, the next step is to see how these results line up against the widely followed Phibro Animal Health narratives, and where the story investors have in mind may need adjusting.

Margins Reset Around 6.3% Net Level

• On a trailing 12 month basis, net profit margin sits at 6.3% compared with 2.7% in the prior year, alongside trailing 12 month net income of US$95.2 million on US$1.5b of revenue.
• What stands out for the bullish narrative is that this margin profile lines up with expectations for profit margins to rise from 6.3% to 9.5%, yet
  • recent quarterly net income has been in a tight band between US$24.0 million and US$27.5 million over the last three quarters, which looks steadier than a story driven only by one off uplift from acquisitions.
  • the bullish view that margin expansion could continue is helped by this consistency, but the step up from 6.3% to 9.5% still requires more improvement than the current quarterly range alone confirms.

Phibro's recent margin performance makes it easier to see why some bullish investors think there is more earnings power to come, yet it also shows how much further margins would need to move to fully match that view. 🐂 Phibro Animal Health Bull Case

Earnings Growth Outpacing Modest 3.1% Revenue Trend

• Trailing 12 month earnings are reported to have grown about 199.6% while revenue growth is projected at roughly 3.1% per year against a reference US market revenue growth of 11.4% per year.
• Bears highlight the risk that slower top line expansion and industry changes could limit future gains, and the current numbers give them mixed evidence to work with,
  • because the revenue trend looks modest relative to that 11.4% market reference, which speaks to their concern that core medicated feed additives and mature segments may not support high growth on their own.
  • yet the very strong trailing earnings growth and higher margin level show that, at least over the last year, profit outcomes have not been constrained by that slower revenue path in the way the bearish story might suggest.

Skeptical investors may focus on the softer revenue trajectory, but the scale of recent earnings growth makes it harder to argue that slower sales have already capped profitability. 🐻 Phibro Animal Health Bear Case

Valuation Signals Pull In Different Directions

• The stock trades at a P/E of 18.4x versus a US Pharmaceuticals industry average of 16.7x and peer average of 14.2x, while the provided DCF fair value is US$118.57 compared with a current share price of US$43.16, implying the share price is roughly 63.6% below that DCF fair value.
• Consensus narrative points to this combination of a premium P/E and a discount to DCF fair value as a key tension for investors,
  • since the 18.4x P/E suggests the market is already paying more per dollar of trailing earnings than the industry and peer groups, which can support the idea that expectations are not low.
  • but the large gap between US$43.16 and the US$118.57 DCF fair value means that, if the cash flow assumptions behind that model hold, the current price does not align with that earnings and cash flow outlook.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Phibro Animal Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards in play, this update gives plenty to think about. Check the full data, stress test your own assumptions, and weigh the company's 3 key rewards and 1 important warning sign using the 3 key rewards and 1 important warning sign.

See What Else Is Out There

Phibro Animal Health pairs modest revenue growth of about 3.1% with a P/E above industry and peer averages, leaving some investors questioning the trade off.

If you want alternatives where pricing looks more in your favor, compare this setup with 51 high quality undervalued stocks and see which stocks line up better with your return goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.